14,272 Shares in Biogen Inc. $BIIB Purchased by Fieldview Capital Management LLC

Fieldview Capital Management LLC purchased a new position in Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 14,272 shares of the biotechnology company’s stock, valued at approximately $2,512,000.

Several other institutional investors have also modified their holdings of the business. Rothschild Investment LLC lifted its stake in shares of Biogen by 12.3% in the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 56 shares in the last quarter. Itau Unibanco Holding S.A. lifted its stake in shares of Biogen by 24.4% in the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 66 shares in the last quarter. Advisory Services Network LLC lifted its stake in shares of Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 68 shares in the last quarter. Davis Investment Partners LLC lifted its stake in shares of Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after acquiring an additional 71 shares in the last quarter. Finally, Optas LLC raised its stake in Biogen by 4.5% during the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 73 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Up 0.0%

NASDAQ:BIIB opened at $200.05 on Friday. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $205.97. The firm has a market capitalization of $29.54 billion, a PE ratio of 21.46 and a beta of 0.20. The stock has a 50 day moving average of $188.73 and a 200-day moving average of $184.31. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the company posted $3.02 EPS. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts predict that Biogen Inc. will post 14.18 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on BIIB shares. Guggenheim upped their price objective on Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Wedbush upped their price objective on Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research note on Thursday, April 30th. Rothschild & Co Redburn upped their price objective on Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. Wall Street Zen upgraded Biogen from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, JPMorgan Chase & Co. upped their price objective on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research note on Thursday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $217.26.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.